CTI BioPharma Corp
CTIC
Market Cap$0
Close$
$9.82
8% upside
Current Fair Value
8% upsideUndervalued by 8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $57.44 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.56 |
| Beta | 0.0 |
| Outstanding Shares | 131,880,176 |
| Avg 30 Day Volume | 0 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | -0.0 |
| Price to Sales | - |
| Price to Book Ratio | -9.09 |
| Enterprise Value to Revenue | 0.76 |
| Enterprise Value to EBIT | -1.07 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.03 |
| Debt to Equity | -4.59 |
Revenue Sources
No data
ESG Score
No data
About CTI BioPharma Corp
CEO: Adam Craig CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers...